Rapport Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | $94.8M | $60.9M | $28.0M |
| SG&A Expense | — | $30.3M | $22.1M | $8.2M |
| Operating Income | — | $-125.1M | $-83.1M | $-36.2M |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | — | — | $-78.3M | $-34.8M |
| Income Tax Expense | — | $0 | $0 | $10.0K |
| Net Income | — | $-111.5M | $-78.3M | $-34.8M |
| Net Margin | — | — | — | — |
| EPS (Basic) | — | $-2.86 | $-3.78 | $-1.65 |
| EPS (Diluted) | — | $-2.86 | $-3.78 | $-1.65 |
| Shares Outstanding (Basic) | 47.8M | 38.9M | 20.7M | 21.1M |
| Shares Outstanding (Diluted) | 47.8M | 38.9M | 20.7M | 21.1M |
| Dividends Per Share | — | — | — | — |